Cargando…
A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies
LESSONS LEARNED: The novel therapeutic vaccine hVEGF(26–104)/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF(26–104)/RFASE failed to induce seroconversion against native hVEGF(165) and, accordingly, neither a decrease in circulating vascular endothelial growth factor (VE...
Autores principales: | Goedegebuure, Ruben S.A., Wentink, Madelon Q., van der Vliet, Hans J., Timmerman, Peter, Griffioen, Arjan W., de Gruijl, Tanja D., Verheul, Henk M.W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873342/ https://www.ncbi.nlm.nih.gov/pubmed/33105058 http://dx.doi.org/10.1002/onco.13576 |
Ejemplares similares
-
A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016) -
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
por: Labots, Mariette, et al.
Publicado: (2018) -
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
por: Huijts, Charlotte M., et al.
Publicado: (2018) -
Short and Long-Term Effects of hVEGF-A(165) in Cre-Activated Transgenic Mice
por: Leppänen, Pia, et al.
Publicado: (2006) -
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019)